PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)

被引：0

作者：

Harrison, C. ^{[1
]}

Szoke, A. ^{[2
]}

Suvorov, A. ^{[3
]}

Egyed, M. ^{[4
]}

Prasad, R. ^{[5
]}

Mayer, J. ^{[6
]}

Jakucs, J. ^{[7
]}

Elinder, A. ^{[8
]}

Recher, C. ^{[9
]}

te Boekhorst, P. A. ^{[10
]}

Knapper, S. ^{[11
]}

Somervaille, T. ^{[12
]}

Ciceri, F. ^{[13
]}

Quddus, F. ^{[14
]}

Straetmans, N. ^{[15
]}

Niederwieser, D. ^{[16
]}

Dean, J. P. ^{[17
]}

Granston, T.

Kiladjian, J. J. ^{[18
]}

Vannucchi, A. ^{[19
]}

Nangalia, J. ^{[20
]}

Mead, A. ^{[21
]}

Mesa, R. ^{[22
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, London, England

[2] Univ Szeged, Albert Szent Gyorgyi Clin Ctr, Szeged, Hungary

[3] Minist Hlth Udmurt Republ, Republican Clin Hosp 1, Izhevsk, Russia

[4] Kaposi Mor Teaching Hosp, Kaposvar, Hungary

[5] Royal Hobart Hosp, Hobart, Tas, Australia

[6] Univ Hosp Brno, Brno, Czech Republic

[7] Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary

[8] North Shore Hosp, Takapuna, New Zealand

[9] Inst Univ Canc Toulouse, Toulouse, France

[10] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

[11] Cardiff Univ, Cardiff, Wales

[12] Christie NHS Fdn Trust, Manchester, Lancs, England

[13] Ist Sci San Raffaele, I-20132 Milan, Italy

[14] Upstate Oncol Associates, Greenville, SC USA

[15] Ctr Hosp Jolimont Lobbes, Haine St Paul, Belgium

[16] Univ Klinikum Leipzig, Leipzig, Germany

[17] CTI BioPharma Corp, Seattle, WA USA

[18] Hop St Louis, Paris, France

[19] Univ Florence, Florence, Italy

[20] Univ Cambridge, Cambridge, England

[21] Univ Oxford, Oxford, England

[22] Mayo Clin, Scottsdale, AZ USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB314

引用

页码：103 / 103

页数：1

共 50 条

[21] Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.
Mesa, Ruben A.
Egyed, Miklos
Szoke, Anita
Suvorov, Aleksandr
Perkins, Andrew
Mayer, Jiri
Ganly, Peter
Schouten, Harry C.
Tosi, Patrizia
Farber, Charles Michael
Zachee, Pierre
Scheid, Christof
Dean, James P.
Granston, Tanya
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Nangalia, Jyoti
Mead, Adam
Harrison, Claire N.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
Mascarenhas, J.
Marcellino, B. K.
Lu, M.
Kremyanskaya, M.
Fabris, F.
Sandy, L.
Mehrotra, M.
Houldsworth, J.
Najfeld, V.
El Jamal, S.
Petersen, B.
Moshier, E.
Hoffman, R.
LEUKEMIA RESEARCH, 2020, 88
[23] A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
Mascarenhas, John O.
Borate, Uma
Bose, Prithviraj
Byrd, John C.
Garcia, Jacqueline S.
Grunwald, Michael R.
Hobbs, Gabriela S.
Hoffman, Ronald
Kuykendall, Andrew T.
Mesa, Ruben A.
Oh, Stephen
Rampal, Raajit
Yacoub, Abdulraheem
Steensma, David P.
BLOOD, 2024, 144 : 31471 - 31473
[24] Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)
Pemmaraju, Naveen
Carter, Bing Z.
Kantarjian, Hagop M.
Cortes, Jorge E.
Kadia, Tapan M.
Garcia-Manero, Guillermo
DiNardo, Courtney D.
Bose, Prithviraj
Pierce, Sherry
Zhou, Lingsha
Estrov, Zeev
Tuttle, Carla Kay
Salinas, Karina
Mak, Po Yee
Verstovsek, Srdan
BLOOD, 2016, 128 (22)
[25] EVIDENCE OF EFFICACY OF RAD001, AN INHIBITOR OF MTOR, IN A PHASE I/II STUDY IN PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PPV/PET MF)
Vannucchi, M.
Guglielmelli, P.
Lupo, L.
Finazzi, M. C.
Tozzi, L.
Biamonte, F.
Antonioli, E.
Bogani, C.
Pieri, L.
Gattoni, E.
Masciulli, A.
Paratore, S.
Susini, M. C.
Finazzi, G.
Marchioli, R.
Rambaldi, A.
Barbui, T.
Bosi, A.
Barosi, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 472 - 472
[26] A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF)
Andersen, C.
Mortensen, N.
Vestergaard, H.
Bjerrum, O.
Klausen, T.
Hasselbalch, H.
HAEMATOLOGICA, 2013, 98 : 120 - 120
[27] RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF)
Vannucchi, Alessandro M.
Guglielmelli, Paola
Gattoni, Elisabetta
Antonioli, Elisabetta
Bogani, Costanza
Tozzi, Lorenzo
Pieri, Lisa
Bosi, Alberto
Rambaldi, Alessandro
Barbui, Tiziano
Barosi, Giovanni
BLOOD, 2009, 114 (22) : 130 - 130
[28] Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient reported outcomes (PROs) in the phase III PERSIST-1 trial.
Mesa, Ruben A.
Harrison, Claire N.
Cervantes, Francisco
Dean, James P.
Wang, Lixia
Granston, Tanya
Yang, Yoojung
Vannucchi, Alessandro M.
Mead, Adam
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF
Talpaz, Moshe
Jamieson, Catriona
Gabrail, Nashat Y.
Lebedinsky, Claudia
Gao, Guozhi
Liu, Feng
Tefferi, Ayalew
Pardanani, Animesh
BLOOD, 2012, 120 (21)
[30] A Phase 1/2, Open-Label, Dose-Escalation, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
Verstovsek, Srdan
Talpaz, Moshe
Ritchie, Ellen K.
Wadleigh, Martha
Odenike, Olatoyosi
Jamieson, Catriona
Stein, Brady L.
Tomonori, Uno
Mesa, Ruben
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →